Alkermes Unveils Phase 1b Data for Narcolepsy Treatment at SLEEP 2024
Alkermes Unveils Phase 1b Data for Narcolepsy Treatment at SLEEP 2024
Alkermes plc (NASDAQ:ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. The data are being presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston.
Alkermes股份有限公司（納斯達克：ALKS）今天宣佈，該公司的創新性、探索性可口服藥物OX2R激動劑ALKS 2680已通過1b期幻覺病1型（NT1）隊列進行全新數據評估，作爲一種一日一次的中樞神經系統（CNS）表現治療醫學用於治療嗜睡病。這些數據正在SLEEP 2024上展示，SLEEP 2024是第38屆APSS（Associated Professional Sleep Societies）年會，於2024年6月1日至5日在休斯頓舉行。
The phase 1b study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 via once-daily, single, oral administration. Ten patients with NT1 were randomized1 to one of four crossover sequences in which each participant received 1 mg, 3 mg and 8 mg of ALKS 2680, and placebo, with washout periods between each treatment. Initial results from the first four patients in this NT1 cohort were previously presented at the 2023 World Sleep Congress.
1b期研究已通過一次日常單次口服ALKS 2680評估其安全性、耐受性、藥代動力學和藥效學。在這項NT1隊列研究中，十名患者已被隨機分配到四個交叉序列之一，每名參與者分別接受了1毫克、3毫克和8毫克的ALKS 2680以及安慰劑，每個治療方案之間有沖洗期。這個NT1隊列的前四名參與者的初步結果已經在2023年世界睡眠大會上發佈。
譯文內容由第三人軟體翻譯。